BIO-TECHNE Corp — Director's Dealing 2016

Aug 22, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2016-08-18

Reporting Person: Gould Kevin S (SVP Clinical Controls)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-18	Stock Options (Right to Buy)	$106.59	A	17371	Acquired	2023-08-18	Common Stock (17371)	Direct
2016-08-18	Stock Options (Right to Buy)	$106.59	A	13028	Acquired	2023-08-18	Common Stock (13028)	Direct
2016-08-18	Restricted Stock Units	$	A	2111	Acquired		Common Stock (2111)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2191	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$97.23	2022-07-09	Common Stock (50000)	50000	Direct
Stock Options (Right to Buy)	$97.23	2022-07-09	Common Stock (15000)	15000	Direct
Stock Options (Right to Buy)	$88.23	2023-01-04	Common Stock (10000)	10000	Direct

Footnotes

F1: Includes 833 shares of restricted stock units that vest on 7/9/17 and 834 shares of restricted stock units that vest on 7/9/18.

F2: 50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/2018.

F3: Vests as to 2,500 shares on each of 01/04/2017, 01/04/2018, 01/04/2019 and 01/04/2020.

F4: Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.

F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.